Economics of Breast Cancer Overdiagnosis and False Positives
Weighing the costs of breast cancer screening and the economic impact of false positives.
Breast cancer screening can save lives, but the economic impact of false-positive mammography results and breast cancer over-diagnosis must be discussed, according to a study published in the journal Health Affairs.
The over-diagnosis rate for breast cancer varies, including 22% of all breast cancer screenings in Canada and 22% to 31% in the US, the authors wrote. However, not much is known about the associated economic cost. In this study, researchers from Boston Children’s Hospital and Harvard Medical School sought to determine these costs among women aged 40 to 59.
The researchers looked at the expenditure data for 12 months following diagnosis from a major US healthcare insurance plan for 702,154 women in this age group from 2011 to 2013.
Determined costs:
“This translates to a national cost of $4 billion each year,” the authors wrote. “The costs associated with false-positive mammograms and breast cancer over-diagnoses appear to be much higher than previously documented. Screening has the potential to save lives. However, the economic impact of false-positive mammography results and breast cancer overdiagnoses must be considered in the debate about the appropriate populations for screening.”
The authors concluded that this economic impact must be considered in the debate about the appropriate populations for screening.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
